$Jazz Pharmaceuticals PLC(JAZZ-To The Moon - Tiger Brokers Online Investing Community - To The Moon

$Jazz Pharmaceuticals PLC(JAZZ)$

Jazz Pharma (JAZZ) soars 5.53% pre-market and now has breached the $230 price.

The significant upward movement appears driven by the company's release of better-than-expected first-quarter 2026 financial results. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, substantially beating the analyst consensus estimate of $4.57. Quarterly revenue reached $1.07 billion, a 19% year-over-year increase that also surpassed expectations. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.

Furthermore, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. Following the earnings release, multiple analysts raised their price targets on the stock, reflecting increased optimism about the company's prospects.

SanDisk Beats but Falls 4% Post-Earnings: Classic Sell the News?

SanDisk (SNDK) delivered above-consensus Q3 revenue and earnings, yet shares dropped 4.42% after hours in a textbook sell-the-news reaction — Seagate's outperformance had already fueled a sustained storage sector rally, raising the bar significantly and pricing in the beat ahead of results. The AI storage demand narrative remains intact. But is SNDK's post-earnings decline a short-term shakeout or an early sign of trend reversal — and would a drop below $1,000 represent a buy signal?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":561478642095112,"tweetId":"561478642095112","gmtCreate":1778111581139,"gmtModify":1778117657964,"author":{"id":4088639346266630,"idStr":"4088639346266630","authorId":4088639346266630,"authorIdStr":"4088639346266630","name":"daz999999999","avatar":"https://community-static.tradeup.com/news/8bbe8cd95504dc1e0dd3af78504d3f7e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":12,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.83%","individualDisplayEnabled":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-3","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":2657,"starInvestorFlag":false},"themes":[{"themeId":"d5665496fe2a45c48c26d62806db3003","categoryId":"7a15628ce2174325bddc6229505e0d70","name":"SanDisk Beats but Falls 4% Post-Earnings: Classic Sell the News?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":d5665496fe2a45c48c26d62806db3003}&rnconfig={\"headerBarHidden\": true}","description":"SanDisk (SNDK) delivered above-consensus Q3 revenue and earnings, yet shares dropped 4.42% after hours in a textbook sell-the-news reaction — Seagate's outperformance had already fueled a sustained storage sector rally, raising the bar significantly and pricing in the beat ahead of results. The AI storage demand narrative remains intact. But is SNDK's post-earnings decline a short-term shakeout or an early sign of trend reversal — and would a drop below $1,000 represent a buy signal?","image":"https://community-static.tradeup.com/news/08f55f3f65deb4eb833679ae7571fa2a"}],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><a href=\"https://ttm.financial/S/JAZZ\">$Jazz Pharmaceuticals PLC(JAZZ)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;\n<p><br></p>\n<p>Jazz Pharma (JAZZ) soars 5.53% pre-market and now has breached the $230 price.</p>\n<p>The significant upward movement appears driven by the company's release of better-than-expected first-quarter 2026 financial results. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, substantially beating the analyst consensus estimate of $4.57. Quarterly revenue reached $1.07 billion, a 19% year-over-year increase that also surpassed expectations. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.</p>\n<p>Furthermore, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. Following the earnings release, multiple analysts raised their price targets on the stock, reflecting increased optimism about the company's prospects.</p>\n<p></p>\n<p><br></p></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/JAZZ\">$Jazz Pharmaceuticals PLC(JAZZ)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;\n<p><br></p>\n<p>Jazz Pharma (JAZZ) soars 5.53% pre-market and now has breached the $230 price.</p>\n<p>The significant upward movement appears driven by the company's release of better-than-expected first-quarter 2026 financial results. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, substantially beating the analyst consensus estimate of $4.57. Quarterly revenue reached $1.07 billion, a 19% year-over-year increase that also surpassed expectations. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.</p>\n<p>Furthermore, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. Following the earnings release, multiple analysts raised their price targets on the stock, reflecting increased optimism about the company's prospects.</p>\n<p></p>\n<p><br></p></body></html>","text":"$Jazz Pharmaceuticals PLC(JAZZ)$ Jazz Pharma (JAZZ) soars 5.53% pre-market and now has breached the $230 price. The significant upward movement appears driven by the company's release of better-than-expected first-quarter 2026 financial results. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, substantially beating the analyst consensus estimate of $4.57. Quarterly revenue reached $1.07 billion, a 19% year-over-year increase that also surpassed expectations. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca. Furthermore, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. Following the earnings release, multiple analysts raised their price targets on the stock, reflecting increased optimism about the company's prospects.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/561478642095112","repostId":0,"isVote":1,"tweetType":1,"viewCount":88,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["JAZZ"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":783,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/561478642095112"}